![Medical News Asia | Powered by ['mediPr]](https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png)
REFINING HER2 IHC ASSESSMENT GUIDED BY CAP REPORTING TEMPLATE: ENABLING ACCURATE CLASSIFICATION ACROSS SOLID TUMORS AND ADDRESSING INTRATUMORAL HETEROGENEITY
The use of IHC staining of tissue samples to guide targeted treatment is widely used in clinical practice, and is recommended by expert groups for many tumor types and biomarkers. [11,12] The classical approach to IHC scoring for biomarkers, such as human epidermal growth factor receptor-2 (HER2), classifies specimens as either ‘positive’ or ‘negative’, scoring samples as IHC0, 1+, 2+ or 3+ per pathologists’ visual interpretation. [11,12]
Achieving the Best Outcomes under COVID-19 Endemicity
The first coronavirus (CoV) outbreak occurred as severe acute respiratory syndrome CoV in 2003 in China, followed by the emergence of the Middle East respiratory syndrome CoV in 2012.
Advancements in Ovarian Cancer Treatment: Insights from ASCO 2024
Ovarian cancer is the 8th most common cancer in women globally, with an age-standardised incidence rate of 6.7 per 100,000 in 2022.
Advancements in Lung Cancer Treatment: Insights from ASCO 2024
Lung cancer remains a leading cause of cancer-related deaths worldwide. Advances in targeted therapies improving the outcome for lung cancer patients were highlighted at the ASCO 2024 conference. A summary of clinical data, focusing on novel treatment options and new combination-therapies.
